Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion–dependent anemia a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Garcia-Manero, Guillermo, Santini, Valeria, Almeida, Antonio, Platzbecker, Uwe, Jonasova, Anna, Silverman, Lewis R., Falantes, Jose, Reda, Gianluigi, Buccisano, Francesco, Fenaux, Pierre, Buckstein, Rena, Diez Campelo, Maria, Larsen, Stephen, Valcarcel, David, Vyas, Paresh, Giai, Valentina, Olíva, Esther Natalie, Shortt, Jake, Niederwieser, Dietger, Mittelman, Moshe, Fianchi, Luana, La Torre, Ignazia, Zhong, Jianhua, Laille, Eric, Lopes de Menezes, Daniel, Skikne, Barry, Beach, C. L., Giagounidis, Aristoteles
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wolters Kluwer Health 2021
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099416/
https://ncbi.nlm.nih.gov/pubmed/33764805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02619
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi